* Androgenetic alopecia (AGA) or common baldness is the most common cause of hair loss in both men and women and is caused by the action of androgens in genetically predisposed individuals. * This clinical trial was designed to evaluate the efficacy and safety of using a preparation of autologous plasma rich in growth factors (PRGF-Endoret) in the treatment of androgenetic alopecia.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
PRGF-Endoret mesotherapy micro injection.
Saline Solution mesotherapy micro injection
Clínica Eduardo Anitua.
Vitoria-Gasteiz, Alava, Spain
Centro dermatológico estético
Alicante, Spain
Change from baseline in Hair density at three months (number of hairs per cm2)
Hair density (number of hairs per cm2) will be measured for each treatment group
Time frame: 3 months post-treatment
Hair Width (micrometers)
Hair width will be measured for each treatment group
Time frame: Basal, 1, 2, and 3 months post-treatment
Anagen/telogen ratio
Hair cycle has different phases. Two of the most important are anagen (active growth phase of hair follicles) and telogen (resting phase of the hair follicle). This secondary outcome measure allows to measure the efficacy of the PRGF-Endoret treatment.
Time frame: Basal, 1, 2, and 3 months post-treatment
Terminal Hair Density
Terminal hair density will be established for each one of the treatments
Time frame: Before each one of the treatments and 1, 2 and 3 months post-treatment.
Vellous hair density
Vellous hair will be measured for each treatment group
Time frame: Basal,1, 2 and 3 months post-treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.